{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T12:01:50Z","timestamp":1762084910029,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1053\/j.seminhematol.2023.03.004","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T03:43:38Z","timestamp":1680061418000},"page":"107-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management"],"prefix":"10.1053","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"E.","family":"Terpos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.R.","family":"Branagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Garc\u00eda-Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Trotman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.M.","family":"Greenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.M.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Morel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Kimby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Frustaci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Hatjiharissi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.P.","family":"Treon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2023.03.004_bib0001","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1097\/HS9.0000000000000433","article-title":"Consensus statement on the management of Waldenstrom Macroglobulinemia patients during the COVID-19 pandemic","volume":"4","author":"Talaulikar","year":"2020","journal-title":"Hemasphere"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0002","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/JCO.21.02419","article-title":"Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the national COVID cohort collaborative","volume":"40","author":"Song","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0003","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1080\/07853890.2022.2031274","article-title":"Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines","volume":"54","author":"Fernandes","year":"2022","journal-title":"Ann Med"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0004","article-title":"Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium","volume":"19","author":"Choueiri","year":"2023","journal-title":"Lancet Reg Health"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0005","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/ajh.26669","article-title":"SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignancies","volume":"97","author":"Terpos","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0006","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.3390\/cancers14235816","article-title":"Low spike antibody levels and impaired BA.4\/5 neutralization in patients with multiple myeloma or Waldenstrom's Macroglobulinemia after BNT162b2 booster vaccination","volume":"14","author":"Rosati","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0007","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1038\/s41591-022-02031-7","article-title":"Safety, immunogenicity and antibody persistence of a bivalent beta-containing booster vaccine against COVID-19: a phase 2\/3 trial","volume":"28","author":"Chalkias","year":"2022","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0008","doi-asserted-by":"crossref","first-page":"119","DOI":"10.15585\/mmwr.mm7205e1","volume":"72","author":"Link-Gelles","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0009","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26887","article-title":"XBB.1.5 neutralizing antibodies upon bivalent COVID-19 vaccination are similar to XBB but lower than BQ.1.1","author":"Devasundaram","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/ajh.26619","article-title":"Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responses","volume":"98","author":"Beaton","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0011","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ccell.2021.12.003","article-title":"Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia","volume":"40","author":"Konishi","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0012","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/bjh.18055","article-title":"Response to vaccination against SARS-CoV-2 in 168 patients with Waldenstrom macroglobulinaemia: a French Innovative Leukaemia Organization study","volume":"197","author":"Tomowiak","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0013","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imbruvica-epar-product-information_en.pdf Accessed March 14, 2023."},{"issue":"S3","key":"10.1053\/j.seminhematol.2023.03.004_bib0014","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1097\/01.HS9.0000851180.32970.18","article-title":"Efficacy of a 3rd covid vaccine, including during a BTKi pause, in individuals with Waldenstrom Macroglobulinemia and follicular lymphoma","volume":"6","author":"Rankin","year":"2022","journal-title":"HemaSphere"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0015","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1182\/bloodadvances.2021005444","article-title":"Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study","volume":"5","author":"Gavriatopoulou","year":"2021","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0016","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10238-021-00746-4","article-title":"Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine","volume":"22","author":"Gavriatopoulou","year":"2022","journal-title":"Clin Exp Med"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0017","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ccell.2021.09.001","article-title":"Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0018","doi-asserted-by":"crossref","first-page":"1654.e1","DOI":"10.1016\/j.cmi.2022.07.015","article-title":"Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients","volume":"28","author":"Nguyen","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0019","article-title":"Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies","volume":"3","author":"Bruel","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0020","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ccell.2022.05.007","article-title":"Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies","volume":"40","author":"Stuver","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0021","unstructured":"Food and Drug Administration. FDA releases important information about risk of COVID-19 due to certain variants not neutralized by Evusheld. 2023. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-releases-important-information-about-risk-covid-19-due-certain-variants-not-neutralized-evusheld. Accessed January 15, 2023."},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0022","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network","volume":"35","author":"Ludwig","year":"2021","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2023.103648","article-title":"Polyclonal immunoglobulins for COVID-19 pre-exposure prophylaxis in immunocompromised patients","author":"Focosi","year":"2023","journal-title":"Transfus Apher Sci"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0024","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/paxlovid-epar-product-information_en.pdf Accessed March 13, 2023."},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0025","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe Covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0026","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0027","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/referral\/lagevrio-also-known-molnupiravir-mk-4482-covid-19-article-53-procedure-conditions-use-conditions_en.pdf Accessed March 13, 2023."},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0028","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.7326\/M22-0729","article-title":"Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19: a randomized, placebo-controlled trial","volume":"175","author":"Johnson","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0029","doi-asserted-by":"crossref","first-page":"e28186","DOI":"10.1002\/jmv.28186","article-title":"Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents","volume":"95","author":"Mazzotta","year":"2023","journal-title":"J Med Virol"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0030","unstructured":"https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-sotrovimab-emergency-use-authorization Accessed April 5, 2022."},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0031","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.16168","article-title":"Ibrutinib monotherapy outside of clinical trial setting in Waldenstrom macroglobulinaemia: practice patterns, toxicities and outcomes","volume":"188","author":"Abeykoon","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0032","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/imm.13416","article-title":"The role of Bruton's tyrosine kinase in the immune system and disease","volume":"164","author":"McDonald","year":"2021","journal-title":"Immunology"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108816","article-title":"BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a systematic review","volume":"230","author":"Stack","year":"2021","journal-title":"Clin Immunol"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0034","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.50647","article-title":"COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis","volume":"6","author":"Senefeld","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0035","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1016\/S2666-5247(21)00030-6","article-title":"Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19","volume":"2","author":"Rodionov","year":"2021","journal-title":"Lancet Microbe"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0036","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/trf.16871","article-title":"How do I implement an outpatient program for the administration of convalescent plasma for COVID-19?","volume":"62","author":"Bloch","year":"2022","journal-title":"Transfusion"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0037","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/jamaoncol.2021.1799","article-title":"Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19","volume":"7","author":"Thompson","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0038","article-title":"Guidance on the use of convalescent plasma to treat immunocompromised patients with COVID-19","author":"Bloch","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0039","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/bloodadvances.2020003880","article-title":"Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias","volume":"5","author":"Branagan","year":"2021","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2023.03.004_bib0040","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.joim.2021.09.001","article-title":"Interventions for preventing influenza: an overview of Cochrane systematic reviews and a Bayesian network meta-analysis","volume":"19","author":"Yuan","year":"2021","journal-title":"J Integr Med"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196323000240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196323000240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:28:48Z","timestamp":1758522528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196323000240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0037196323000240"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2023.03.004","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2023.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}